FDA Issues Final Potency Guidance for Gene Therapies
The guidance gives manufacturers recommendations for verifying that cellular and gene therapy batches meet defined potency standards before reaching patients.
Updated on Nov. 2, 2026 in Biotech
The FDA has issued final guidance on potency assurance for cellular and gene therapy products, replacing its 2011 potency testing guidance. The document offers flexible, risk-based recommendations covering development from early investigational submissions through approval and post-market verification.
Why it matters
The guidance applies to treatments for serious and often life-threatening conditions, and it aims to support faster access to safe and effective therapies for patients who often have no other options. Manufacturers are legally required to show their products work as intended throughout their lifecycle.
The final guidance replaces FDA's 2011 potency testing guidance, marking a formal update to the agency's framework for cellular and gene therapies. Specific numerical potency thresholds are not specified in the available details, and manufacturers will need to consult the document for product-specific recommendations.
The players
U.S. Food and Drug Administration (FDA)
The federal agency responsible for regulating drugs, biologics, and medical products in the United States, including cellular and gene therapies, and the issuer of this final guidance.
The details
The guidance covers controls for variability in raw materials, testing during manufacturing, and laboratory assays confirming each batch is biologically active. It also addresses products with short shelf lives, viral vector gene therapies, and patient-specific therapies.
Timeline
November 2, 2026: FDA issues final potency assurance guidance for cellular and gene therapy manufacturers.
December 10, 2026: FDA holds a webinar to help stakeholders understand and implement the guidance.
Big Picture
The new guidance replaces FDA's 2011 potency testing guidance, expanding the agency's earlier approach into a risk-based framework that spans from early investigational submissions through post-market verification. It moves potency oversight from a testing-focused standard toward integrated lifecycle controls for cellular and gene therapies.
Manufacturers developing cellular and gene therapies must now build potency verification into each batch and development stage under the updated framework. Patients with serious conditions could see therapies move more efficiently toward approval if these recommendations are followed.
The takeaway
Developers and patients alike should watch for how the risk-based approach shapes approval timelines for cellular and gene therapies. Stakeholders can prepare by reviewing the guidance and attending the December 10, 2026 FDA webinar.
What happens next
FDA will hold a webinar on December 10, 2026 to help stakeholders understand and implement the guidance.
Further reading
Explore more Biotech coverage for context on cellular and gene therapy regulation.
More information
Read the FDA press announcement on CGT potency guidance from the U.S. Food and Drug Administration.
